Results 91 to 100 of about 74,341 (223)

Development and targeted use of nilotinib in chronic myeloid leukemia

Drug Design, Development and Therapy, 2008
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour   +3 more
doaj  

Salivary Methotrexate as a Predictor of Oral Mucositis in Hematological Cancer Patients: A Phase II Randomized, Double‐Blind Clinical Trial

Oral Diseases, EarlyView.
ABSTRACT Objective To evaluate the efficacy of prophylactic photobiomodulation therapy (PBMT) in preventing oral mucositis (OM) and to assess serum and salivary methotrexate (MTX) levels as predictors of OM in adults receiving high‐dose methotrexate (HD‐MTX).
Letícia Rodrigues‐Oliveira, Carolina Guimarães Bonfim, Ana Leticia Mores, Natalia Rangel Palmier, Henrique Ballassini Abdalla, Juliana Trindade Clemente‐Napimoga, Iara Gonçalves Aquino, Maria Cecilia Querido de Oliveira, Maria Cláudia Cuzzullin, Aljomar Jose Vechiato Filho, Cesar Rivera, Tatiana Natasha Toporcov, Juliana Pereira, Luiz Alcino Gueiros, Rossana Veronica Mendoza López, Manoela Domingues Martins, Marcelo Lazzaron Lamers, Karina Morais‐Faria, Pablo Agustin Vargas, Alan Roger Santos‐Silva, Thais Bianca Brandão, Ana Carolina Prado‐Ribeiro   +21 more
wiley   +1 more source

Algorithm for Surgical Management in Patients in Treatment With Medication Associated With Osteonecrosis of the Jaws

Oral Surgery, EarlyView.
ABSTRACT Background Osteonecrosis of the jaws is associated with various drugs, including antiresorptives such as bisphosphonates and denosumab, as well as antiangiogenics. These drugs are used for the treatment of multiple diseases, notably osteoporosis, bone metastases, Paget's disease, osteogenesis imperfecta, malignant hypocalcaemia, among others ...
Rodríguez Naranjo Julia Alexandra, Gómez Hernández Kevin Andrew, Cabrera del Cid María Fernanda, Jerez Robalino James Philippe   +3 more
wiley   +1 more source

Treatment‐free remission in CML patients with prior TKI failure is not influenced by previous BCR::ABL1 kinase domain mutations

British Journal of Haematology, EarlyView.
Simone Claudiani, Silvia Metelli, Myrto Katraki, Fiona Fernando, Andrew J. Innes, Chloe Hayden, Dragana Milojkovic   +6 more
wiley   +1 more source

Cancer‐associated fibroblast heterogeneity across solid and haematological malignancies: Lessons from colorectal cancer and multiple myeloma

The Journal of Physiology, EarlyView.
Abstract figure legend CAF origins and plasticity give rise to distinct phenotypes with immunosuppressive functions in colorectal cancer and multiple myeloma. These distinct CAF phenotypes contribute to immunosuppressive tumour microenvironments through ECM remodelling, cytokine signalling and immune regulation.
Hui Mo, Haoyan Han, Michael O'Dwyer, Eileen Reidy, Aideen E. Ryan   +4 more
wiley   +1 more source

Imatinib-induced pseudoporphyria

, 2009
P>Imatinib, a synthetic tyrosine kinase inhibitor, is used as first-line therapy for chronic myeloid leukaemia. Imatinib treatment is associated with a variety of adverse effects, most of which are mild to moderate and generally abate after the first ...
Vos - Kardaun, Sylvia, Timmer-de Mik, L., Kramer, M. H. H., Hayes, D. P., Bousema, M. T.   +4 more
core   +1 more source

Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting

International Journal of Nanomedicine, 2014
Peng Ye,1,2 Wendian Zhang,1 Tan Yang,1 Yao Lu,1 Miao Lu,1 Yongkang Gai,1 Xiang Ma,1 Guangya Xiang1 1School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of ...
Ye P, Zhang W, Yang T, Lu Y, Lu M, Gai Y, Ma X, Xiang G   +7 more
doaj  

Structural Basis for the Regulation of PPARγ Activity by Imatinib

Molecules, 2019
Imatinib is an effective anticancer drug for the treatment of leukemia. Interestingly, when an FDA-approved drug library was tested for agents that block peroxisome proliferator-activated receptor γ (PPARγ) phosphorylation at Ser245 to evaluate
Jun Young Jang, Hyun-Jung Kim, Byung Woo Han   +2 more
doaj   +1 more source

Outcomes for post‐transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study

British Journal of Haematology, EarlyView.
Alexandros Rampotas, Amy A. Kirkwood, Maximillian Brodermann, Nicola Maciocia, Fotios Panitsas, Sridhar Chaganti, Styliani Bouziana, Emma Nicholson, Samantha Drummond, Michelle Lannon, Amy Publicover, Sharon Allen, Isaac Gannon, Andrew J. King, Anne‐Louise Latif, Henry Crosland, Claire Roddie   +16 more
wiley   +1 more source

New Hydrazone Derivatives Featuring Isatin and Piperazine Moieties: Synthesis, Cytotoxicity Evaluation, and Molecular Modeling Studies

Journal of Applied Toxicology, Volume 46, Issue 12, Page 4583-4598, December 2026.
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü, Münevver Baran, Miyase Gözde Gündüz, Şengül Dilem Doğan   +3 more
wiley   +1 more source